While biologic drugs have been a boon to immunology, many of them are monoclonal antibodies able to address only individual targets. Multiple pathways are typically involved in inflammation, so blocking one leaves others open to continue driving disease. Bambusa Therapeutics calls this limitation of single-target drugs a “therapeutic ceiling.”
Bambusa is developing antibodies engineered to hit multiple targets, breaking the therapeutic ceiling. With a lead bispecific antibody in early clinical testing for atopic dermatitis and more multi-target antibodies in the pipeline, Bambusa has secured $169 million in IPO cash for its research.
“We believe that next-generation therapeutic approaches, particularly bispecific and multi-target biologics that simultaneously modulate complementary and synergistic inflammatory pathways, are necessary to expand responder populations, address the significant unmet medical need, and unify treatment across overlapping disease biology,” the company said in the IPO filing.
Automation Didn’t Dehumanize Care. Bad Systems Did.
We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring.
Investor interest in Bambusa’s approach enabled the biotech to increase the deal size by adding more than 1.2 million shares than planned. On Thursday night, the Boston-based company offered about 10.5 million shares priced at $16 each, which was the midpoint of the targeted price range. Those shares began trading on the Nasdaq Friday under the stock symbol “BBTX.”
Lead drug candidate BBT001 is a long-acting bispecific antibody designed to block interleukin-4 receptor alpha (IL-4R alpha) and interleukin-31 (IL-31). Both targets have clinical and commercial validation from blockbuster antibody I&I drugs that hit the targets separately. Sanofi’s Dupixent blocks IL-4R alpha; Novartis’s Cosentyx is an IL-31 inhibitor. Bambusa contends blocking both targets with a single drug could simultaneously address type 2 inflammation and chronic itch, which are the two defining burdens of inflammatory skin disorders such as atopic dermatitis.
BBT001 is currently being evaluated in a global Phase 1 study in atopic dermatitis. In the filing, Bambusa said preliminary results show the study drug led to a fast onset effect that led to improvement according to a rating scale of disease severity. These early results also show rapid itch relief as well as robust and durable suppression of the biological indicators of type 2 inflammation. To date, BBT001 has been well tolerated with no cases of conjunctivitis (a known side effect of Dupixent, particularly in atopic dermatitis). This drug engineered with an extended half-life. Bambusa said the preclinical and clinical data so far could support quarterly dosing, which would be an advantage over injections of Dupixent every two weeks.
Bambusa touts pipeline-in-a-molecule potential for BBT001. Beyond atopic dermatitis, other indications the company is considering for the asset include prurigo nodularis, alopecia areata, bullous pemphigoid, and chronic pruritus of unknown origin.
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
The next program, BBT002, is a bispecific antibody designed to target IL-4R alpha and interleukin-5 (IL-5). The latter target is validated by Nucala, a blockbuster GSK drug with approvals in asthma and chronic obstructive pulmonary disease (COPD). In the filing, Bambusa said blocking both pathways with a single drug could offer broader control of the inflammation that drives inflammatory respiratory diseases compared to medicines that address just one pathway. In COPD, Bambusa is running a global Phase 1 study and a Phase 1/2a study in China. A Phase 2 study in China is evaluating the drug in chronic rhinosinusitis with nasal polyps.
Bambusa’s two clinical-stage programs trace their origins to Biotheus, a China-based antibody specialist that is now a BioNTech subsidiary following an acquisition last year. BioNTech’s main interest in Biotheus was bispecific antibodies for treating cancer. Bambusa acquired the Biotheus antibodies that became BBT001 and BBT002 and advanced them to the clinic.
Bambusa has also identified two additional drug candidates in partnership with the BioNTech subsidiary. One of them, a long-acting bispecific antibody designed to target TL1A and IL-23p19, is expected to enter the clinic by the end of this year for inflammatory bowel disease (IBD). This candidate, BBT003, could compete with TL1-A inhibitors in development by partners Teva Pharmaceutical and Sanofi, Merck, and Roche. Newly capitalized companies with multi-specific drugs addressing these targets include Attovia Therapeutics and Bionyra Pharma.
Bambusa formed in 2024, backed by about $15 million in seed financing. In early 2025, Bambusa announced a $90 million Series A round. Later that year and early this year, a Series A-2 financing brought in an additional $33.1 million according to the filing. Bambusa’s largest shareholder was Salvia Investment, which held a 22% stake prior to the IPO, the filing shows. Bambusa co-founder and CEO Shanshan Xu ,a former BioNTech business development executive, owned a 21.2% stake before the company went public.
As of the end of June, Bambusa reported its cash position was $71.6 million. With the infusion of IPO proceeds, the biotech expects to have enough capital to last into late 2028. Bambusa plans to spend about $90 million for the ongoing development of lead program BBT001, advancing it to the start of a planned Phase 2 test in atopic dermatitis. Another $40 million is budgeted to bring BBT002 into Phase 2b testing in a respiratory indication. The remaining capital will go toward the rest of its pipeline, including BBT003 in IBD and BBT004, a bispecific antibody designed to deplete pathogenic B cells and antibody-producing plasma cells.
Aspen Neuro Nabs $140M for Regenerative Medicine Approach to Parkinson’s
Aspen Neuroscience raised $140.6 million in IPO proceeds to support clinical testing of its Parkinson’s disease cell therapy. Late Thursday, the San Diego-based biotech priced its offering of more than 9.3 million shares at $15 each, which was the low end of its targeted price range. Those shares will trade on the Nasdaq under the stock symbol “ASPE.”
In Parkinson’s, patients lack the neurotransmitter dopamine. Standard treatment is levodopa, a drug that is converted to dopamine in the body to boost levels of this key brain chemical. Aspen’s regenerative medicine approach aims to restore a patient’s ability to produce dopamine. The company’s cell replacement therapy, sasineprocel (formerly known as ANPD001) is made with induced pluripotent stem cells (iPSCs), cells that have the potential to become almost any type of cell in the body.
Aspen makes sasineprocel by programing the iSPCs to become dopamine-producing neurons. The stem cells come from a biopsy of a patient’s skin — using a patient’s own cells is intended to reduce the risk of rejection by the immune system. That could be a competitive advantage compared to other approaches, such as that of BlueRock Therapeutics. The Bayer subsidiary makes its cell therapy with iPSCs sourced from healthy donors. Such allogeneic cell therapies require immunosuppression to prevent rejection.
Sasineprocel, which is intended to be a one-time treatment, is administered as an injection into the brain using a standard neurosurgical technique. An open-label Phase 1/2 study is evaluating two dose levels. Aspen expects to report long-term data from this study in the first half of 2028. The company is also looking ahead to Phase 3 testing. In the IPO filing, Aspen said it expects to start collecting biopsies for the planned pivotal study by the end of this year, followed by patient dosing in the second half of next year.
Aspen’s science is based on the iPSC research of Jeanne Loring, a scientist at Scripps Research. Since Aspen’s formation in 2018, the company said it had raised $347 million as a private company. The most recent financing was a $115 million Series C round last November co-led by OrbiMed, Arch Venture Partners, Frazier Life Sciences, and Revelation Partners; Gilead Sciences also participated as a new investor in the company. Orbimed’s 13.1% stake prior made it Aspen’s largest shareholder prior to the IPO, followed by the 12.3% owned by Arch Venture Partners and the 8.4% stake of Gilead Sciences, the filing shows. As of the end of June, Aspen reported its unaudited cash position was $72.4 million.
Aspen plans to spend about $8 million to continue the Phase 1/2a test of sasineprocel in sporadic and genetic Parkinson’s; $110 million is budgeted for starting and financing the Phase 3 trial. Aspen also plans to spend about $4 million to continue development of it preclinical microglia programs. The company estimates its cash will last into the second half of 2028.
Photo: Getty Images